Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Pembrolizumab vs Intravenous Pembrolizumab in First-line Metastatic NSCLC
NCT05722015Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
A Phase 3 trial of berahyaluronidase alfa + pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Feb 2023; status: active, not recruiting.
02
Drugs
berahyaluronidase alfa + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05722015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722015.